Driving CAR therapies beyond T cells.

Area of Science:

• Immunology
• Oncology
• Biotechnology

Background:

• Chimeric antigen receptor (CAR)-T cell therapy has revolutionized treatment for hematological malignancies.
• Significant challenges, including physical barriers, antigen heterogeneity, and immunosuppressive tumor microenvironments, limit CAR-T cell efficacy in solid tumors.
• Safety concerns also complicate the selection of appropriate targets for CAR-T cell therapy in solid tumors.

Purpose of the Study:

• To review recent advances in emerging CAR platforms beyond T cells for solid tumor immunotherapy.
• To compare the biological and translational features of these alternative CAR platforms.
• To outline strategies for integrating cell-intrinsic properties with CAR design for next-generation cellular immunotherapies.

Main Methods:

• Literature review of recent advances in CAR technology applied to alternative immune cell lineages.
• Comparative analysis of biological and translational characteristics of various CAR platforms.
• Discussion of CAR design principles and cell-intrinsic properties for solid tumor applications.

Main Results:

• CAR technology is being extended to alternative immune lineages like macrophages, natural killer cells, tumor-infiltrating lymphocytes, and unconventional T cells.
• These alternative CAR platforms offer complementary mechanisms for tumor recognition, infiltration, and immune modulation in solid tumors.
• Integrating cell-intrinsic properties with CAR design is crucial for enhancing efficacy and overcoming solid tumor challenges.

Conclusions:

• Emerging CAR platforms utilizing alternative immune cells present a promising avenue for advancing solid tumor immunotherapy.
• Overcoming physical barriers, antigen heterogeneity, and the immunosuppressive tumor microenvironment are key areas for development.
• Future cellular immunotherapies for solid tumors will likely benefit from tailored CAR designs and optimized cell-intrinsic properties.